Last reviewed · How we verify

GSK573719 + GW642444 62.5/25 — Competitive Intelligence Brief

GSK573719 + GW642444 62.5/25 (GSK573719 + GW642444 62.5/25) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) M3 muscarinic receptor; beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GSK573719 + GW642444 62.5/25 (GSK573719 + GW642444 62.5/25) — GlaxoSmithKline. GSK573719 (umeclidinium) and GW642444 (vilanterol) work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK573719 + GW642444 62.5/25 TARGET GSK573719 + GW642444 62.5/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) M3 muscarinic receptor; beta-2 adrenergic receptor
Glycopyrrolate + Formoterol Glycopyrrolate + Formoterol Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination M3 muscarinic receptor; beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg Revefenacin 175 µg, Formoterol 20 µg University of Tennessee Graduate School of Medicine marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Aclidinium bromide & formoterol fumarate Aclidinium bromide & formoterol fumarate University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler Umeclidinium / Vilanterol Dry Powder Inhaler Gary L. Pierce marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
GSK573719/GW642444 Inhalation Powder GSK573719/GW642444 Inhalation Powder GlaxoSmithKline phase 3 LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK573719 + GW642444 62.5/25 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk573719-gw642444-62-5-25. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: